medigraphic.com
ISSN 1561-3186 (Electronic)

2022, Number 4

<< Back Next >>

Rev Acta Médica 2022; 23 (4)

Immunohistochemical markers of microsatellite instability for the typing of colorectal cancer. Key aspects for interpretation by the pathologist

López SMC, Monteagudo CF, Rodríguez TM, García MG

Language: Spanish
References: 12
Page:
PDF size: 222.90 Kb.


ABSTRACT

Introduction: Microsatellite instability are mutations in simple repetitive sequences characterizing the DNA of tumor cells, since it leads to damages in the protein system that repairs mismatches. Detecting these affectations is at present a powerful diagnostic tool allowing to know the stage of the tumor and predicting its behavior.
Objective: To guide the pathologist in the interpretation of the Ventana Roche immunohistochemistry system for the detection of the presence or absence of expression of DNA error repair system proteins in colorectal cancer.
Methods: Ventana Roche immunohistochemical system was applied to determine the presence or absence of repair proteins MLH1, MSH2, MSH6 and PMS2.
Results: A tumor with high microsatellite instability was identified as it did not express the presence of HML1 and PSM2 proteins.
Conclusions: Ventana Roche system integrates monoclonal antibodies directed against the proteins MLH1, MSH2, MSH6 and PMS2. Its correct interpretation allows obtaining a more accurate classification of the colon tumor and suggests or rules out the subsequent need for genetic testing.


REFERENCES

  1. Somarelli J, Gardner H, Cannataro V, Gunady E, Boddy A, Johnson N, et al. Molecular biology and evolution of cancer: from discovery to action. Mol Biol Evol. 2020;37(2):320-6. DOI: https://doi.org/10.1093/molbev/msz242

  2. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. DOI: https://doi.org/10.5114/pg.2018.81072

  3. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clinicians. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660

  4. Nehs I, Samar A, Suzan M, Eman M. Mismatch repair proteins and microsatellite instability in colorectal carcinoma (MLH1, MSH2, MSH66 y PMS2) histopathological and immunohistochemical study. Macedonian J Medical Sciences. 2017;5(1). DOI: https://doi.org/10.3889/oamjms.2017.003

  5. Tieng F, Abu N, Lee L, Mutalib N. Microsatellite instability in colorectal cancer liquid biopsy-current updates on its potential in non-invasive detection, prognosis and as a predictive marker. Diagnostics. 2021;11(3):544. DOI: https://doi.org/10.3390/diagnostics11030544

  6. Rodas O, Oregón E. Identificaciones del fenotipo de inestabilidad microsatelital en carcinoma colorrectal mediante el análisis de la expresión de proteínas reparadoras del ADN: revisión narrativa. Ciencia, Tecnolog Salud. 2021;8(2). DOI: https://doi.org/10.36829/63cts.v8i2.945

  7. Baracaldo R, Peña L, Gómez O, Polo F, López P, Parra R. Características histopatológicas del carcinoma colorrectal con inestabilidad microsatelital (IMS). Fund Univ Cienc Salud. 2020 [acceso: 20/02/2022];29(1):[aprox. 9p.]. Disponible en: https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/172

  8. Li K, Luo H, Huang L, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Internat. 2020;20(1):16. DOI: https://doi.org/10.1186/s12935-019-1091-8

  9. Gian L, Lorena B, Cinzia A. Microsatellite instability in colorectal cáncer. Acta Biomed. 2018;89(9):[aprox. 5 p.]. DOI: https://doi:10.23750/abm.v89i9-s.7960

  10. Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T, et al. Esmo recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with pd-1/pd-l1 expression and tumour mutational burden: a systematic review-based approach. Annals Oncology. 2019;30(8):1232-43. DOI: https://doi.org/10.1093/annonc/mdz116

  11. Provenzale D, Gupta S, Ahnen D, Bray T, Cannon J, Cooper G, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, nccn clinical practice guidelines in oncology. J National Comprehensive Cancer Network. 2016;14(8):1010-30. DOI: https://doi.org/10.6004/jnccn.2016.0108

  12. Roche Tissue Diagnostics. Our mission is to improve the lives of all patients afflicted with cancer. Roche Tissue Diagnostics. 2020 [acceso: 20/02/2022]. Disponible en: https://diagnostics.roche.com/global/en/about/roche-tissue-diagnostics.html




2020     |     www.medigraphic.com